The CX3CR1 protein level did not differ in a trigeminal neuralgia model before or after BoNT treatment [16], but it was reported that the mRNA expression of this chemokine receptor selectively expressed in microglia was upregulated in scenarios of depression induced by chronic administration of reserpine in a Parkinson disease model, which was significantly decreased in the hippocampus in the experimental group using BoNT [18]. This evidence concerns the gene CX3CR1 and trigeminal nerve disorder.